Midazolam nasal spray to treat intermittent, stereotypic episodes of frequent seizure activity: pharmacology and clinical role, a comprehensive review
An intranasal formulation of midazolam, Nayzilam, has been FDA-approved to treat intermittent, stereotypic episodes of frequent seizure activity. Nayzilam is easy to administer and can quickly treat seizures that occur outside of the hospital. The intra-nasal route of administration allows non-medical personal to administer the drug which makes it more accessible and user-friendly in the event of a seizure. Many studies have indicated quick cessation of seizures with Nayzilam compared to rectal diazepam, which has been the standard of care treatment. Nayzilam has been proven to be safe and effective for acute seizures in children, deeming it a revolutionary alternative in times where intravenous administration is not possible.
1. Humphries LK, Eiland LS. Treatment of Acute Seizures: Is Intranasal Midazolam a Viable Option? J Pediatr Pharmacol Ther. 2013;18(2):79-87. doi:10.5863/1551-6776-18.2.79
2. Griffin CE, Kaye AM, Rivera Bueno F, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214-223. Accessed August 25, 2020. http://ccforum.com/
3. UCB announces NAYZILAM®(midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
4. Kalviainen R. Intranasal therapies for acute seizures. Epilepsy Behav. 2015;49:303-306. doi:10.1016/j.yebeh.2015.04.027
5. Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend. 2019;200:95-114. doi:10.1016/j.drugalcdep.2019.02.033
6. Fluyau D, Revadigar N, Manobianco BE. Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol. 2018;8(5):147-168. doi:10.1177/2045125317753340
7. Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health. 2016;106(4):686-688. doi:10.2105/ajph.2016.303061
8. Tan KR, Brown M, Labouebe G, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010;463(7282):769-774. doi:10.1038/nature08758
9. Okada H, Matsushita N, Kobayashi K, Kobayashi K. Identification of GABAA receptor subunit variants in midbrain dopaminergic neurons. J Neurochem. 2004;89(1):7-14. doi:10.1111/j.1471-4159.2004.02271.x
10. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes. Nature. 1999;401(6755):796-800. doi:10.1038/44579
11. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci. 2009;10(8):561-572. doi:10.1038/nrn2515
12. Best KM, Boullata JI, Curley MAQ. Risk factors associated with iatrogenic opioid and benzodiazepine withdrawal in critically ill pediatric patients: A systematic review and conceptual model. Pediatr Crit Care Med. 2015;16(2):175-183. doi:10.1097/pcc.0000000000000306
13. Bergman I, Steeves M, Burckart G, Thompson A. Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administration. J Pediatr. 1991;119(4):644-649. doi:10.1016/s0022-3476(05)82420-5
14. Sheridan RL, McEttrick M, Bacha G, Stoddard F, Tompkins RG. Midazolam infusion in pediatric patients with burns who are undergoing mechanical ventilation. J Burn Care Rehabil. 1994;15(6):515-518. doi:10.1097/00004630-199411000-00009
15. METS B, HORSELL A, LINTON DM. Midazolam-induced benzodiazepine withdrawal syndrome. Anaesthesia. 1991;46(1):28-29. doi:10.1111/j.1365-2044.1991.tb09309.x
16. Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38(5):152-155. doi:10.18773/austprescr.2015.05
17. Al-Qattan MM, Al-Humsi TR, Al-Ahdab MF. Withdrawal syndrome following prolonged sedation in a burn patient. Biomed Res. Published online 2014.
18. fda, cder. HIGHLIGHTS OF PRESCRIBING INFORMATION.
19. Hudak ML, Tan RC, Frattarelli DAC, et al. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540-e560. doi:10.1542/peds.2011-3212
20. Madden JD, Chappel JN, Zuspan F, Gumpel J, Mejia A, Davis R. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol. 1977;127(2):199-201. doi:10.1016/s0002-9378(16)33250-1
21. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010;38(6):981-987. doi:10.1124/dmd.110.032094
22. Nayzilam (midazolam) Nasal Spray Medication Guide.
23. Sigel E, Steinmann ME. Structure, function, and modulation of GABAA receptors. J Biol Chem. 2012;287(48):40224-40231. doi:10.1074/jbc.r112.386664
24. Zhu S, Noviello CM, Teng J, Walsh RM Jr, Kim JJ, Hibbs RE. Structure of a human synaptic GABAA receptor. Nature. 2018;559(7712):67-72. doi:10.1038/s41586-018-0255-3
25. Kanto JH. Midazolam: The First Water-soluble Benzodiazepine; Pharmacology, Pharmacokinetics and Efficacy in Insomnia and Anesthesia. Pharmacother J Hum Pharmacol Drug Ther. 1985;5(3):138-155. doi:10.1002/j.1875-9114.1985.tb03411.x
26. Koul RL, Aithala GR, Chacko A, Joshi R, Elbualy MS. Continuous midazolam infusion as treatment of status epilepticus. Arch Dis Child. 1997;76(5):445-448. doi:10.1136/adc.76.5.445
27. Gallais H, Casanova P, Fabregat H. Midazolam and oxazepam in the treatment of insomnia in hospitalized patients. Br J Clin Pharmacol. 1983;16(S1):145S-149S. doi:10.1111/j.1365-2125.1983.tb02286.x
28. Midazolam - StatPearls - NCBI Bookshelf.
29. Smith R, Brown J. Midazolam for status epilepticus. Aust Prescr. 2017;40(1):23-25. doi:10.18773/austprescr.2017.005
30. nayzilam Clinical Pharmacology Drug Monograph.
31. Information for Patients | NAYZILAM®(midazolam) nasal spray, CIV.
32. Allali J, Chauve C, Denise A, et al. BRASERO: A resource for benchmarking RNA secondary structure comparison algorithms. Adv Bioinformatics. 2012;2012(893048):5. doi:10.1155/2012
33. Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng TC, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters - a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60(9):1797-1808. doi:10.1111/epi.15159
34. Javadzadeh M, Sheibani K, Hashemieh M, Saneifard H. Intranasal midazolam compared with intravenous diazepam in patients suffering from acute seizure: A randomized clinical trial. Iran J Pediatr. 2012;22(1):1-8.
35. Berg AK, Myrvik MJ, Van Ess PJ. Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults. Epilepsy Behav. 2017;71:51-59. doi:10.1016/j.yebeh.2017.02.023
36. von Blomberg A, Kay L, Knake S, et al. Efficacy, tolerability, and safety of concentrated intranasal midazolam spray as emergency medication in epilepsy patients during video-EEG monitoring. CNS Drugs. 2020;34(5):545-553. doi:10.1007/s40263-020-00720-w
37. Kay L, Merkel N, von Blomberg A, et al. Intranasal midazolam as first-line in-hospital treatment for status epilepticus: a pharmaco-EEG cohort study. Ann Clin Transl Neurol. 2019;6(12):2413-2425. doi:10.1002/acn3.50932
38. Babbar N, Nanda S, Rohilla A. INTRANASAL MIDAZOLAM FOR THE TREATMENT OF SEIZURES IN CHILDREN IN RURAL INDIA. Indian J Child Health. 2020;7(1):12-14. doi:10.32677/ijch.2020.v07.i01.003
39. Owusu KA, Dhakar MB, Bautista C, et al. Comparison of intranasal midazolam versus intravenous lorazepam for seizure termination and prevention of seizure clusters in the adult epilepsy monitoring unit. Epilepsy Behav. 2019;98:161-167. doi:10.1016/j.yebeh.2019.07.021
40. Holsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med. 2010;164(8):747-753. doi:10.1001/archpediatrics.2010.130
41. Holsti M, Sill BL, Firth SD, Filloux FM, Joyce SM, Furnival RA. Prehospital Intranasal Midazolam for the Treatment of Pediatric Seizures. Pediatr Emerg Care. 2007;23(3):148-153. doi:10.1097/pec.0b013e3180328c92
42. Lahat E, Goldman M, Barr J, Eshel G, Berkovitch M. Intranasal midazolam for childhood seizures. Lancet. 1998;352(9128):620. doi:10.1016/s0140-6736(05)79574-x
43. Kutlu NO, Yakinci C, Dogrul M, Durmaz Y. Intranasal midazolam for prolonged convulsive seizures. Brain Dev. 2000;22(6):359-361. doi:10.1016/s0387-7604(00)00155-8
44. Bhattacharyya M, Kalra V, Gulati S. Intranasal Midazolam vs Rectal Diazepam in Acute Childhood Seizures. Pediatr Neurol. 2006;34(5):355-359. doi:10.1016/j.pediatrneurol.2005.09.006
45. Fisgin T, Gurer Y, Tezic T, et al. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: Prospective randomized study. J Child Neurol. 2002;17(2):123-126. doi:10.1177/088307380201700206